SNY250117P80000
- 0.00
- 0.000.00%
Sanofi Newsroom
Earnings Preview: Sanofi to Report Financial Results Pre-market on January 30
How Is The Market Feeling About Sanofi?
J.P. Morgan Sticks to Their Hold Rating for Sanofi (SNYNF)
Sanofi Advances With Cialis Trial and EU Approval for Sarclisa
Vigil Neuroscience Gains as Alzheimer's Drug Reaches Mid-stage Trial
UBS Sticks to Its Buy Rating for Sanofi (SNYNF)
Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses
Sanofi Announces Expanded Marketing Authorization For Sarclisa In The EU - Quick Facts
EU Approves Sarclisa In Combination With VRd As A Treatment For Transplant-Ineligible Adults With Newly Diagnosed Multiple Myeloma
Press Release: Sarclisa Approved in the EU as the First Anti-CD38 Therapy in Combination With Standard-of-care VRd to Treat Transplant-ineligible Newly Diagnosed Multiple Myeloma
Sanofi Receives GMP Warning Letter for Genzyme Facility
Sanofi's Consumer Healthcare Unit Gets OK to Trial Cialis as Over-the-counter Medicine in US
Opella, Part Of Sanofi, Secures FDA Clearance To Begin Trial For OTC Cialis
Sanofi (SNY.US) "star small molecule" protein degraders new drug has been approved for clinical use in China.
The "Star Small Molecule" protein degrader new drug from Sanofi (SNY.US) has been approved for clinical use in China.
Press Release: Opella Reaches Study Milestone for Cialis
SK Bioscience and Sanofi's GBP410 Vaccine Enters Global Phase III Trials
Sanofi's Growth Prospects and Undervalued Position Highlighted by Analyst Graham Parry
Sanofi Set For a Robust 2025 -- Market Talk
Express News | 'As Bird Flu Affects More People And Animals, CDC Urges Faster Testing' - Washington Post
Sanofi Hits 10-week High